Intelligent Bio slumps after proposed public offering
** Shares of diagnostic tests developer Intelligent Bio
Solutions Inc INBS.O fall ~45% to $3.25 premarket
** Co announces public offering of shares of its common
stock and warrants
** INBS has 916,265 shares outstanding - Refinitiv data
** Co had cash and cash equivalents of $2.9 mln as of Dec.
31, 2022
** Ladenburg Thalmann & Co Inc is acting as the sole
bookrunning manager for the offering - INBS
** INBS shares have fallen ~39% in the past six months
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study